Clinical trials: Hematological Malignancy, open to volunteers
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
- Trial name
- TAGVEN (NCT07007052)
- Testing
- Venetoclax, Tagraxofusp
- Where
- 34 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Hematologic Malignancy, Neutropenia
Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers).
- Conditions
- Hematologic Malignancy, Neutropenia, Bone Pain
- Trial name
- NCT07300735
- Testing
- Loratadine, Diosmin-Hesperidin, Loratadine + Diosmin-Hesperidin
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Alexandria University
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematologic Malignancies, Hematopoietic Stem Cell Transplantation
Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation
This study investigates whether a resistance training program can help patients recovering from hematopoietic stem cell transplantation (HSCT) for hematologic malignancies.
- Conditions
- Hematologic Malignancies, Hematopoietic Stem Cell Transplantation, Resistance Training, Neutropenia
- Trial name
- NCT07872813
- Testing
- 8-week Elastic Band Resistance Training Program
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections.
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Secondary Immunodeficiency (SID)
- Trial name
- PRO-SID (NCT06821880)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
T-cell Lymphoma, T-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma.
- Trial name
- NCT03829540
- Testing
- CD4CAR
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Huda Salman
Haematological Malignancy, Hypogammaglobulinemia
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics…
- Trial name
- RATIONALISE (NCT05678621)
- Testing
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins
- Where
- 7 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Monash University
Hematologic Malignancies
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT06378138
- Testing
- ICP-248, Orelabrutinib
- Where
- 53 sites in China
- Volunteers
- 226 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Hematologic Malignancy, Solid Tumor
Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.
The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal…
- Trial name
- NCT07570563
- Testing
- Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese PLA General Hospital
Hematologic Malignancies, Hematologic Neoplasms
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone.
- Trial name
- NCT07162038
- Testing
- mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Neoplasms
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose [RP2D]) of JNJ-95804306.
- Trial name
- NCT07572006
- Testing
- JNJ-95804306, AML SoC, CLL/SLL SoC
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Janssen Research & Development, LLC
Haematological Malignancy
Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy
It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation.
- Trial name
- APALLO (NCT05379738)
- Testing
- 6 sessions of adapted physical activity after stem cell transplant
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Breast Cancer, Gastrointestinal Cancer
Improving Comprehensive Care of Cancer Patients
Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support.
- Conditions
- Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
- Trial name
- NCT05323409
- Testing
- OPTIMISE
- Where
- United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia
Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by clonal proliferation of myeloid precursors in the bone marrow, leading to impaired hematopoiesis and bone marrow failure[1,2].
- Trial name
- NCT07343687
- Volunteers
- 80 people
- Sponsor
- Assiut University
Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
- Trial name
- NCT06756321
- Testing
- anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Affiliated Hospital of Nantong University
Hematologic Malignancies, Solid Cancer
Elderly CAncer Patient
The management of older patients with cancer has become a major public health concern in Western countries because of the aging of the population and steady increase in cancer incidence with advancing age.
- Trial name
- ELCAPA (NCT02884375)
- Testing
- Extensive GA
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polycythemia Vera
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
- Trial name
- GIV-IN-PV (NCT06093672)
- Testing
- Givinostat, Hydroxyurea
- Where
- 90 sites in United States, Austria and 14 more
- Volunteers
- 220 people
- Sponsor
- Italfarmaco
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
This randomized clinical trial studies how well non-invasive ventilation works in reducing the need for intubation, or placement of a tube in the windpipe, in patients with cancer and respiratory failure.
- Trial name
- NCT02464696
- Testing
- Methylprednisolone, Oxygen Therapy, Positive Air Pressure Device
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center